In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor

Nicoletta Dozio, Marina Scavini, Angelo Beretta, Stefano Sartori, Franco Meschi, Elena Sarugeri, Guido Pozza

Research output: Contribution to journalArticle

Abstract

Patients with mutations affecting insulin receptor function may maintain some degree of metabolic control. The hypothesis has been put forth that in these patients, fuels may be metabolized through pathways (i.e. receptor activation) that become relevant in such abnormal conditions. The aim of our study was to evaluate the metabolic effects of insulin-like growth factor-I (IGF-I) in a 19-yr-old patient with homozygous mutation of the insulin receptor α-subunit. Her metabolic and hormonal features were marked hyperglycemia (11-33 mmol/L) and hyperinsulinemia (1000-2000 pmol/L); normal free fatty acids and lactate; low IGF-I; glycerol, alanine, and pyruvate below the normal range; and elevated β-hydroxybutyrate. Unlike diabetic ketoacidosis, no triglyceride or protein breakdown was present, suggesting a compensatory mechanism, possibly sustained by the insulin concentration acting on IGF-I receptors. Subcutaneous administration of IGF-I (40, 80, and 120 μg/kg), although not affecting plasma glucose, resulted in a rapid decrease in free fatty acids and prevented the rise of β-hydroxybutyrate levels compared to placebo. Therefore, IGF-I can exert direct metabolic effects in vivo, probably through activation of its own receptor, even at a concentration not affecting blood glucose levels. Furthermore, these findings are consistent with the hypothesis that IGF-I receptors may be activated by high insulin levels, providing lipid and protein regulation in patients with nonfunctional insulin receptors.

Original languageEnglish
Pages (from-to)1325-1328
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume80
Issue number4
DOIs
Publication statusPublished - Apr 1995

Fingerprint

Insulin Receptor
Insulin-Like Growth Factor I
Hydroxybutyrates
IGF Type 1 Receptor
Nonesterified Fatty Acids
Chemical activation
Insulin
Diabetic Ketoacidosis
Mutation
Hyperinsulinism
Pyruvic Acid
Hyperglycemia
Alanine
Glycerol
Blood Glucose
Lactic Acid
Reference Values
Triglycerides
Proteins
Placebos

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor. / Dozio, Nicoletta; Scavini, Marina; Beretta, Angelo; Sartori, Stefano; Meschi, Franco; Sarugeri, Elena; Pozza, Guido.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 80, No. 4, 04.1995, p. 1325-1328.

Research output: Contribution to journalArticle

Dozio, Nicoletta ; Scavini, Marina ; Beretta, Angelo ; Sartori, Stefano ; Meschi, Franco ; Sarugeri, Elena ; Pozza, Guido. / In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor. In: Journal of Clinical Endocrinology and Metabolism. 1995 ; Vol. 80, No. 4. pp. 1325-1328.
@article{2d70bbd36a6b47f0b706aa795ab71280,
title = "In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor",
abstract = "Patients with mutations affecting insulin receptor function may maintain some degree of metabolic control. The hypothesis has been put forth that in these patients, fuels may be metabolized through pathways (i.e. receptor activation) that become relevant in such abnormal conditions. The aim of our study was to evaluate the metabolic effects of insulin-like growth factor-I (IGF-I) in a 19-yr-old patient with homozygous mutation of the insulin receptor α-subunit. Her metabolic and hormonal features were marked hyperglycemia (11-33 mmol/L) and hyperinsulinemia (1000-2000 pmol/L); normal free fatty acids and lactate; low IGF-I; glycerol, alanine, and pyruvate below the normal range; and elevated β-hydroxybutyrate. Unlike diabetic ketoacidosis, no triglyceride or protein breakdown was present, suggesting a compensatory mechanism, possibly sustained by the insulin concentration acting on IGF-I receptors. Subcutaneous administration of IGF-I (40, 80, and 120 μg/kg), although not affecting plasma glucose, resulted in a rapid decrease in free fatty acids and prevented the rise of β-hydroxybutyrate levels compared to placebo. Therefore, IGF-I can exert direct metabolic effects in vivo, probably through activation of its own receptor, even at a concentration not affecting blood glucose levels. Furthermore, these findings are consistent with the hypothesis that IGF-I receptors may be activated by high insulin levels, providing lipid and protein regulation in patients with nonfunctional insulin receptors.",
author = "Nicoletta Dozio and Marina Scavini and Angelo Beretta and Stefano Sartori and Franco Meschi and Elena Sarugeri and Guido Pozza",
year = "1995",
month = "4",
doi = "10.1210/jc.80.4.1325",
language = "English",
volume = "80",
pages = "1325--1328",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor

AU - Dozio, Nicoletta

AU - Scavini, Marina

AU - Beretta, Angelo

AU - Sartori, Stefano

AU - Meschi, Franco

AU - Sarugeri, Elena

AU - Pozza, Guido

PY - 1995/4

Y1 - 1995/4

N2 - Patients with mutations affecting insulin receptor function may maintain some degree of metabolic control. The hypothesis has been put forth that in these patients, fuels may be metabolized through pathways (i.e. receptor activation) that become relevant in such abnormal conditions. The aim of our study was to evaluate the metabolic effects of insulin-like growth factor-I (IGF-I) in a 19-yr-old patient with homozygous mutation of the insulin receptor α-subunit. Her metabolic and hormonal features were marked hyperglycemia (11-33 mmol/L) and hyperinsulinemia (1000-2000 pmol/L); normal free fatty acids and lactate; low IGF-I; glycerol, alanine, and pyruvate below the normal range; and elevated β-hydroxybutyrate. Unlike diabetic ketoacidosis, no triglyceride or protein breakdown was present, suggesting a compensatory mechanism, possibly sustained by the insulin concentration acting on IGF-I receptors. Subcutaneous administration of IGF-I (40, 80, and 120 μg/kg), although not affecting plasma glucose, resulted in a rapid decrease in free fatty acids and prevented the rise of β-hydroxybutyrate levels compared to placebo. Therefore, IGF-I can exert direct metabolic effects in vivo, probably through activation of its own receptor, even at a concentration not affecting blood glucose levels. Furthermore, these findings are consistent with the hypothesis that IGF-I receptors may be activated by high insulin levels, providing lipid and protein regulation in patients with nonfunctional insulin receptors.

AB - Patients with mutations affecting insulin receptor function may maintain some degree of metabolic control. The hypothesis has been put forth that in these patients, fuels may be metabolized through pathways (i.e. receptor activation) that become relevant in such abnormal conditions. The aim of our study was to evaluate the metabolic effects of insulin-like growth factor-I (IGF-I) in a 19-yr-old patient with homozygous mutation of the insulin receptor α-subunit. Her metabolic and hormonal features were marked hyperglycemia (11-33 mmol/L) and hyperinsulinemia (1000-2000 pmol/L); normal free fatty acids and lactate; low IGF-I; glycerol, alanine, and pyruvate below the normal range; and elevated β-hydroxybutyrate. Unlike diabetic ketoacidosis, no triglyceride or protein breakdown was present, suggesting a compensatory mechanism, possibly sustained by the insulin concentration acting on IGF-I receptors. Subcutaneous administration of IGF-I (40, 80, and 120 μg/kg), although not affecting plasma glucose, resulted in a rapid decrease in free fatty acids and prevented the rise of β-hydroxybutyrate levels compared to placebo. Therefore, IGF-I can exert direct metabolic effects in vivo, probably through activation of its own receptor, even at a concentration not affecting blood glucose levels. Furthermore, these findings are consistent with the hypothesis that IGF-I receptors may be activated by high insulin levels, providing lipid and protein regulation in patients with nonfunctional insulin receptors.

UR - http://www.scopus.com/inward/record.url?scp=0028923114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028923114&partnerID=8YFLogxK

U2 - 10.1210/jc.80.4.1325

DO - 10.1210/jc.80.4.1325

M3 - Article

C2 - 7714106

AN - SCOPUS:0028923114

VL - 80

SP - 1325

EP - 1328

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -